Birkenfeld, July 28, 2006

The capital increase of Euro 7,416,478.00 from company funds resolved by the Annual General Meeting of STRATEC Biomedical Systems AG on June 23, 2006 was entered in the Commercial Register on July 14, 2006.

In the period between the Annual General Meeting and the entry of the execution of the capital increase from company funds in the Commercial Register, a total of 10,750 shares were issued from conditional capital as a result of the exercising of stock option rights. For this reason, the bonus shares will be allocated to all shareholders on the increased volume of outstanding shares prior to the execution of the capital increase from company funds.

Company shareholders are entitled to bonus shares on the basis of their previous shareholdings at a ratio of 1 : 1.9942188, which means that 1.9942188 new shares (bonus shares) are allocable for each share held. The new shares will participate for the first time in the profit for the 2006 financial year.

The bonus shares will be posted to shareholders from July 31, 2006 by means of a credit to their securities accounts based on their securities account holdings on the evening of July 28, 2006. This will not involve any expense for shareholders. Securities account holders are not required to take any steps in connection with the receipt of the bonus shares. However, should any partial rights arise in their holdings as a result of the allocation ratio of 1 : 1.9942188, then shareholders will be informed by their account-holding banks of any measures possibly required (granting of purchase or sale orders for partial rights). The securities-related aspects of the aforementioned measures are being handled by WestLB AG, Düsseldorf.

The bonus shares are admitted by law to the regulated markets of the subsection of the Frankfurt Stock Exchange involving additional admissions criteria (Prime Standard), as well as to the Gate-M segment of the Stuttgart Stock Exchange. Starting on July 31, 2006, they will be available on the stock exchange by analogy with the old shares and will be included in the ongoing listing. From this date onwards, the old shares will be traded "ex bonus shares".

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges.

The STRATEC Group comprises the listed holding company "STRATEC Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen", "Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: [email protected]

--- End of Message --- WKN: 728900; ISIN: DE0007289001; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in Börse Stuttgart, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf;